Abstract | Chronic kidney disease (CKD) is becoming a worldwide epidemic, driven largely by the dramatic rise in the prevalence of diabetes and obesity. Novel targets and treatments for CKD are, therefore, desperately needed-to both mitigate the burden of this disease in the general population and reduce the necessity for renal replacement therapy in individual patients. This Review highlights new insights into the mechanisms that contribute to CKD, and approaches that might facilitate the development of disease-arresting therapies for CKD. Particular focus is given to therapeutic approaches using antifibrotic agents that target the transforming growth factor β superfamily. In addition, we discuss new insights regarding the roles of vascular calcification, the NADPH oxidase family, and inflammation in the pathogenesis of CKD. We also highlight a new understanding regarding kidney energy sensing pathways (AMPK, sirtuins, and mTOR) in a variety of kidney diseases and how they are linked to inflammation and fibrosis. Finally, exciting new insights have been made into the role of mitochondrial function and mitochondrial biogenesis in relation to progressive kidney disease. Prospective therapeutics based on these findings will hopefully renew hope for clinicians and patients in the near future.
Introduction
Chronic kidney disease (CKD) has become a major burden on the economies of many countries and severely impairs the quality of life of affected patients. The prevalence of CKD is estimated to be 8-16% worldwide. 1 The number of patients requiring renal replacement therapies has also increased tremendously over the past decade, with currently >500,000 patients on dialysis in the USA alone. Kidney disease was ranked the eighteenth most common cause of mortality in 2010, and CKD was ranked third highest for years of life lost due to premature mortality (82%), behind only AIDS and diabetes mellitus. 1 The market for dialysis is worth over US$60 billion worldwide and expected to grow considerably in the next 5 years. 2 With the ongoing rise in the prevalence of diabetes, which is expected to continue, and the lag time between onset of diabetes and late-stage complications, the prevalence of CKD will likely increase even more dramatically in the future.
The current therapeutic strategy for treating diabetic and nondiabetic CKD largely involves the control of hyperglycaemia, dyslipidaemia, and systemic blood pressure ( Figure 1 ). Although activation of the reninangiotensin-aldosterone system (RAAS) has a central role in hypertension, and RAAS blockade has beneficial effects in terms of reducing albuminuria and slowing the progression of CKD, an urgent demand clearly exists for novel disease-modifying therapies that can arrest the progression of CKD.
The role of TGF-β in renal fibrosis
Robust evidence suggests that essentially all progressive forms of CKD are characterized by marked accumulation of extracellular matrix proteins in the glomerulus and tubulointerstitium. As progressive fibrosis might be a driving force for the disruption of glomerular and tubular architecture, inhibition of the major mediators responsible for matrix accumulation might slow or arrest the progression of CKD. Support for this concept has been provided by the results of a number of studies in animal models of CKD, in which inhibiting factors that promote fibrosis, such as transforming growth factor β (TGF-β), connective tissue growth factor (CTGF), and myofibroblast activation, [3] [4] [5] [6] [7] or enhancing factors that attenuate fibrosis, such as bone morpho genetic protein 7 (BMP-7) and hepatocyte growth factor (HGF), 8, 9 improved renal architecture and/or function (Table 1) . Renal fibrosis is the final common manifestation defining CKD and is characterized by progressive tissue scarring that leads to glomerulosclerosis and tubulo interstitial fibrosis. 10 Although the precise sequence of molecular events that result in renal fibrosis has not been completely elucidated, present data indicate that TGF-β is the master regulator of this process. TGF-β is the major driver of matrix synthesis, inhibition of matrix degradation, and myofibroblast activation.
Therapeutic agents that inhibit TGF-β have been shown to reduce matrix accumulation in animal models ■ The incidence of chronic kidney disease (CKD) has increased dramatically over the past 10 years, and new strategies for slowing its progression are urgently needed ■ Many novel approaches to control renal fibrosis in CKD are currently in clinical development ■ NADPH oxidase isoforms have emerged as important mediators of vascular dysfunction, inflammation, and fibrosis in CKD ■ New insights into the role of vascular calcification in the pathogenesis of CKD have led to novel therapeutic approaches, which are under preclinical and clinical development ■ Further animal studies and clinical trials are urgently needed to determine the potential beneficial effects of activating energy-sensing molecules in slowing the progression of CKD ■ Mitochondrial function and biogenesis are now considered as active players in the development of CKD been tested in experimental models of CKD, such as the administration of neutralizing anti-TGF-β antibodies, [3] [4] [5] 12 soluble TGF-β receptor 14 or small interfering RNAs that target the TGF-β type II receptor (Table 1) . 15 These therapies reduced structural renal injury and decreased renal fibrosis. Interestingly, although anti-TGF-β antibodies reduced matrix accumulation in glomerular and tubulointer stitial disease, reductions in albuminuria were not consistently observed, demonstrating that the two processes might operate through separate pathways. In 2011, the results of a phase I clinical trial of fresolimumab, an anti-TGF-β antibody, showed that this agent was well tolerated in patients with primary resistant focal segmental glomerulo sclerosis (FSGS). 16 Phase II studies of another anti-TGF-β antibody, LY2382770, are ongoing in patients with either refractory FSGS or diabetic nephropathy.
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Although TGF-β has a central and dominant role in renal fibrosis, inhibition of TGF-β might promote inflammation and epithelial cell proliferation as well as inhibit fibrosis. CTGF, which is also closely associated with the progression of renal fibrosis but is thought to act downstream of TGF-β, [18] [19] [20] might, therefore, be a more fibrosisspecific target than TGF-β itself. The results of a phase I trial of FG-3019, an anti-CTGF antibody, demonstrated that this agent reduced albuminuria in patients with diabetic nephropathy. 21 Other trials of FG-3019 in combination with angiotensin-converting-enzyme inhibitors and/ or angiotensin-receptor blockers have been conducted in patients with diabetic nephropathy.
22,23 A further trial of FG-3019 was conducted in patients with steroidresistant FSGS. 24 The principal objective of these trials was to assess the safety and tolerability of FG-3019 as well as to determine its effect on proteinuria. However, the phase II trial in patients with diabetic kidney disease was stopped early; the FSGC trial has been completed, but the results are not yet publicly available.
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Several oral agents have been shown to delay the progression of renal fibrosis in animal models of CKD. Pirfenidone is an orally bioavailable compound that inhibits TGF-β as well as platelet-derived growth factor and tumour necrosis factor (TNF) via unknown mechanisms. Several studies in animal models of CKD have demonstrated beneficial effects of pirfenidone in reducing extracellular matrix accumulation and inflammatory cell infiltration. 25, 26 An exploratory clinical trial of pirfenidone in 77 patients with diabetic nephropathy has been completed 27 in which an encouraging beneficial effect on the mean estimated glomerular filtration rate (eGFR), but not on proteinuria, was observed at a dose of 1,200 mg daily. 27 Baseline levels of plasma biomarkers of inflammation and fibrosis-such as TNF, soluble TNF receptor, and fibroblast growth factor 23 (FGF-23)-correlated with baseline eGFR in these patients, but did not predict a response to pirfenidone treatment. 27 Although these results are promising, the lack of effect on albuminuria and on the measured biomarkers makes pirfenidone dosing and monitoring its effect challenging.
Tranilast, another oral antifibrotic agent, reduced glomerulosclerosis, tubulointerstitial fibrosis, and renal Figure 1 | Specific targets and potential therapeutic strategies to inhibit or slow the progression of CKD. There is a complex feed-forward relationship between the initiating factors (hyperglycaemia, obesity, hypertension, bone and mineral disorders) and cardiovascular disorders that stimulate and regulate a variety of major pathways leading to CKD and its complications. Inhibiting intrinsic renal pathways linked to inflammation (NADPH oxidase) and fibrosis (Smads, TGF-β, and CTGF) might prove beneficial. A possible central pathway would be the activation of AMPK that can reduce both inflammatory and profibrotic pathways. Abbreviations: AICAR, AMP analogue; AMPK, 5'-AMP-activated protein kinase; BMP-7, bone morphogenetic protein 7; CKD, chronic kidney disease; CTGF, connective tissue growth factor; EMT, epithelial-mesenchymal transition; HGF, hepatocyte growth factor; NF, nuclear factor; NOX, NADPH oxidase; R, receptor; ROS, reactive oxygen species; Smad, mothers against decapentaplegic homologue; TGF-β, transforming growth factor β; USF, upstream stimulatory factor. 
Preclinical studies
Anti-TGF-β antibody Lepr db/db diabetic mice 3, 4 Reduction in plasma TGF-β1 levels, prevention of increases in plasma creatinine levels and glomerular mesangial matrix expansion, associated with decreased renal mRNAs encoding collagen IV and fibronectin Anti-TGF-β antibody Rats with chronic allograft rejection nephropathy 5 Reduction of proteinuria, attenuation of mononuclear cell infiltration and interstitial fibrosis along with downregulation of mRNA levels of TGF-β1, TGF-β2, and proinflammatory cytokines, or with upregulation of mRNA levels of HGF, BMP-5, and BMP-7
Anti-TGF-β antibody Mice with STZ-induced diabetes 12 Prevention of glomerular hypertrophy, attenuated gain in kidney weight, and attenuation of increased mRNA levels of TGF-β1, type II TGF-β receptor, collagen IV, and fibronectin Anti-TGF-β antibody Rats with puromycin aminonucleoside nephropathy 13 Reduction of TGF-β isoform mRNA expression and collagen III production, and amelioration of histological sclerosis with low dose of antibody Encouraging results for increased mean eGFR but without improvement in proteinuria inflammation in animal models of CKD. [28] [29] [30] [31] Two smallscale clinical studies, conducted in nine and 20 patients with diabetic nephropathy, respectively, demonstrated that tranilast treatment showed promise for slowing the progression of renal disease. 32, 33 An analogue of tranilast, FT061, has demonstrated encouraging beneficial effects in in vitro and in vivo models by reducing collagen production through inhibition of TGF-β in renal mesangial cells, as well as preventing worsening of albuminuria in a rat model of diabetic nephropathy. 6 Another oral analogue of tranilast, FT011, has been tested for antifibrotic effects in experimental models of kidney and heart fibrosis. 34 In two different rat models of CKD (5/6 nephrectomized rats and hypertensive Ren-2 transgenic rats with streptozotocin-induced diabetes), FT011 reduced protein uria, inflammation, and glomerulosclerosis.
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FT011 also had a cardioprotective role in the diabetic Ren-2 rat model, attenuating cardiomyocyte hypertrophy as well as macrophage infiltration and interstitial fibrosis of heart tissue. A phase I clinical trial demonstrated safety and tolerability of FT011 in healthy volunteers and patients with type 2 diabetes mellitus who had diabetic nephropathy. 36 A secondary outcome of this clinical study is also ongoing to evaluate the effect of FT011 on kidney function. 36 The results of this trial could provide a new perspective in preventing the progression of renal fibrosis in patients with CKD.
Various studies have focused on potential inter ventions downstream of TGF-β signalling. Although testing of TGF-β receptor kinase inhibitors has not advanced to clinical studies, several approaches involve interruption of mothers against decapentaplegic homologue (Smad)-a mediator of TGF-β activity-post-receptor signalling. For example, the effects of FT011 might be mediated via inhibition of pathways involving Smad2 and mitogen-activated protein kinases 1 and 3. 34 Moreover, Smad3 has emerged as potentially the most important receptor-regulated phospho peptide in the Smad family in relation to matrix accumulation: knock out of Smad3 protects against diabetic nephropathy, hypertensive kidney disease, and obstructive nephro pathy. 37 Importantly, Smad3 is also phosphorylated via stimulation of angiotensin II, indepen dent of TGF-β.
36 Smad4 is a cofactor involved in all Smad-mediated signalling that has emerged as essential for transcriptional initiation of Smad3 target genes. Deletion of Smad4 in tubular epithelial cells, tubulointerstitial fibroblasts, and mesangial cells protects against TGF-β-induced matrix accumulation. 37 ,38 TGF-β-induced stimulation of a variety of microRNAs (miR-21, miR-29, and miR-192) is mediated via Smad3. 39 Blocking miR-21 39 and miR-192 40 seems to be a promising approach to inhibit TGF-β-induced fibrosis, and this strategy is being considered for clinical studies. BMP-7 is another member of the TGF-β super family. Signalling via BMP-7 receptors results in phosphorylation of Smad1, Smad5, and Smad8. As Bmp7 -/-mice die of renal failure 41 and BMP-7 levels are reduced in patients with CKD, 42, 43 this protein has been recognized as a potential therapeutic agent in this setting. BMP-7 administration attenuates renal fibrosis and, probably via Smad7, inhibits TGF-β signalling. 44 Although administration of BMP-7 itself might be of limited use in clinical practice, owing to its propensity to induce soft tissue calcification, treatments based on BMP-7 receptor agonists or modulating antagonists of BMP-7 seem to show promise. 45 HGF is well known to promote tissue repair in many diseases, and is also considered to function as an antifibrotic regulator in CKD. Its biological actions in the kidney depend on the cell type. The administration of anti-HGF antibodies to rats or mice with CKD worsened progression of tubulointerstitial fibrosis, suggesting a role for HGF in suppressing fibrosis. 46, 47 In addition, treatment with exogenous HGF was effective in terms of ameliorating declining renal function and decreasing fibrosis in various experimental models of CKD (including 5/6 nephrectomized rats, renal allograft recipients, animals with diabetic nephropathy, and aristolochic acid-induced nephrotoxicity). 46, [48] [49] [50] [51] [52] [53] Testis-specific Y-encoded-like protein 2 (TSPY-like protein 2, also known as cell division autoantigen 1 or CDA1) has been highlighted as a potential target to reduce renal TGF-β signalling. 54, 55 CDA1 was first considered for its antiproliferative effects; 56 however, the critical role of CDA1 in TGF-β signalling was demonstrated To assess safety and tolerability of FG3019; trial terminated
Abbreviations: α-SMA, α smooth muscle actin; ACE, angiotensin-converting enzyme; ACR, albumin:creatinine ratio; ARB, angiotensin receptor blocker; BMP, bone morphogenetic protein; CDA1, cell division autoantigen 1; CKD, chronic kidney disease; CTGF, connective tissue growth factor; ECM, extracellular matrix; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; HGF, hepatocyte growth factor; siRNA, small interfering RNA; Smad3, mothers against decapentaplegic homologue 3; STZ, streptozotocin; TGF-β, transforming growth factor β; UUO, unilateral ureteral obstruction.
in models of diabetic nephropathy. CDA1 was upregulated in tubular cells and podocytes in rodent and human diabetic kidneys. 54 In the same study, knockdown of CDA1 in cultured cells reduced production of extracellular matrix proteins and TGF-β-stimulated expression of genes encoding collagen I and collagen III. In a separate study, the role of TSPY-like protein 2 in regulating TGF-β signalling was demonstrated. 55 In diabetic Tspyl2 -/-mice there was reduced renal accumulation of extra cellular matrix proteins and decreased glomerular and tubulo interstitial injury were observed, along with decreased gene expression of TGF-β and TGF-β type I receptor, and decreased levels of phosphorylated Smad3. 55 Interestingly, targeted deletion of Tspyl2 did not affect other features, such as hyperglycaemia, renal hypertrophy, or hyperfiltration, in these diabetic mice. 55 Although additional studies are required to evaluate the potential effect of CDA1 inhib ition on sustained proteinuria and progressive fibrosis, its actions in reducing TGF-β-mediated matrix accumulation provide support for CDA1 as a potential therapeutic target to slow the progression of CKD.
Vascular calcification factors
Vascular calcification and associated hyperphosphataemia is a common feature in CKD and both type 1 and type 2 diabetes mellitus. Studies of the effects of FGF-23 and Klotho have revealed many new insights regarding the pathogenesis of vascular calcification. Although FGF-23 is produced by bone, the kidney is its principal target organ-FGF-23 (along with Klotho) increases urinary phosphate excretion and suppresses production of 1,25-dihydroxyvitamin D 3 . In addition, FGF-23 acts on the parathyroid gland to decrease the secretion of para thyroid hormone, and has been identified as a potential mediator of cardiac hypertrophy in patients with CKD (through a Klotho-independent pathway). 57 The actions of FGF-23 occur through FGF receptors and Klotho. 58 Klotho is produced in the tubular epithelium of the kidney and exists in membrane-bound as well as soluble forms. 59 The membrane-bound form of Klotho acts as a co-receptor for FGF-23 on renal tubular cells, where it augments the phosphaturic activity of FGF-23. 59 Circulating levels of FGF-23 in humans increase with decreasing renal function, reaching very high concentrations in patients with end-stage renal disease. 60, 61 This observation is likely to represent a compensatory response to maintain the phosphate balance. However, since the progressive decline of renal function and the loss of functional nephrons in individuals with CKD lead to decreased Klotho expression in the kidney, the ability of FGF-23 to increase urinary phosphate excretion is limited. A potential therapeutic approach to targeting FGF-23 could involve administration of neutralizing anti-FGF-23 antibodies; however, inhibition of FGF-23 might not be appropriate in the early stages of renal disease owing to the resulting inhibition of phosphaturia.
In view of the aforementioned results, the role of Klotho in vascular calcification is attracting considerable interest.
New insight into the roles of Klotho has been gained by studying Klotho-knockout (Kl/ -/-) mice, which have severe vascular calcification and CKD. 62 Klotho has a beneficial role in preserving phosphat uria and the glomerular filtration rate, but also acts on vascular smooth muscle to suppress dedifferentiation of vascular smooth muscle cells (Table 2) . Of note, loss of Klotho contributes to renal fibrosis. Klotho-mediated regulation of aldosterone might have a role in vascular calcification, as Kl -/-mice seem to have hyperaldosteron ism; 63 treatment of these mice with spironolactone reduces vascular calcification and moderately increases survival. 64 Key regulators of vascular calcification (such as sodium-dependent phosphate transporter 1, TNF, homeobox protein MSX2, and others) are upregulated in the aorta of Kl -/-mice, although expression levels could be reduced with spino rolactone treatment. 64 Moreover, vascular smooth muscle cells express mineralocorticoid receptors, and activation of these receptors leads to differentiation and mineralization of human vascular smooth muscle cells. [64] [65] [66] The emerging recognition of this connection between Klotho-aldosterone signalling and vascular calcification requires further validation in additional animal models and in humans; nevertheless, many options exist for targeting this pathway, thereby improving kidney and cardiovascular disease ( Table 2) .
Administration of exogenous Klotho has a potent antifibrotic effect, as Klotho seems to be an endogenous antagonist of Wnt-β-catenin activity, which promotes fibrogenesis. 67 In addition, Klotho seems to be inhibited by TGF-β, and increased secretion of Klotho has a role in suppressing myofibroblast activation. 67 Loss of Klotho in renal tissue might, therefore, lead to progression of renal fibrosis. Future studies exploring the antifibrotic potential of Klotho might reveal therapeutic potential. 67 
Oxidative stress and NADPH oxidases
The critical role of oxidative stress as a mechanism underlying all diabetic complications has been emphasized. 68 According to this view, the initial increase in mitochondrial superoxide (driven by exposure to high glucose levels) resulting from increased electron transport chain activity contributes to alterations in downstream pathways, such as stimulation of protein kinase C signalling, increased intracellular formation of advanced glycation end-products, and upregulation of the sorbitol pathway. [68] [69] [70] [71] Although clear evidence from numerous groups attests to increased production of specific reactive oxygen species (ROS), 72, 73 demonstration that mitochondrial superoxide production is increased, and is the initial catalyst of downstream deleterious pathways, remains to be established. In this context, the NADPH oxidases might act downstream of mitochondrial superoxide production driven by the electron transport chain. These enzymes are widely expressed in the kidney and well-known to be a major source of ROS.
Several publications have focused on isoforms of these enzymes as potential major sources of oxidant production in CKD. 74, 75 Of the major isoforms that have been identified, NOX-1, NOX-2 (also known as cytochrome b-245 heavy chain), and NOX-4 are expressed in both rodent 76 and human 77 kidneys and might have a role in mediating oxidative stress in CKD by promoting vascular dysfunction, inflammation, and fibrosis. 74, 78 By contrast, little is known about the role of NOX-5 in kidney disease, as it is only expressed in human kidneys. Transgenic mice with podocyte-specific expression of human NOX-5 (Nox5 pod+ ) develop albumin uria, podocyte foot process effacement, and elevated blood pressure. 79 These changes were all shown to be exacer bated in animals with streptozotocin-induced dia betes. 79 Moreover, NOX-5 expression was increased in kidney biopsy specimens from patients with diabetic nephropathy. 79 The results of this study represent a first step towards an improved understanding of the role of NOX-5 in the development of kidney diseases.
Although the roles of NOX-1, NOX-2, and NOX-4 in kidney disease have not been fully elucidated, several studies have provided new insights. Our group found that NOX-2-knockout mice (Nox2 -/-) have the same degree of hyperglycaemia and weight loss after induction of dia betes using streptozotocin as is observed in wild-type mice with streptozotocin-induced dia betes; furthermore, the degree of diabetic nephropathy was unchanged in the Nox2 -/-mice with streptozotocin-induced diabetes. 74 The degree of albumin uria, glomerular matrix expansion, and urinary levels of hydrogen peroxide were all essentially the same in both groups (wild-type and Nox2 -/-) of diabetic mice. As expression of NOX-4 was markedly increased in the kidneys of diabetic Nox2 -/-mice, it is possible that upregulation of NOX-4 compensates for NOX-2 deficiency, and might be sufficient to promote diabetic nephropathy. By contrast, the utility of simultaneously inhibiting NOX-1 and NOX-4 was demonstrated in studies of GKT136901, a dual inhibitor of NOX-1 and NOX-4. 80, 81 Markers of oxidative stress and pro fibrotic signalling were reduced in mouse proximal tubule cells exposed to high glucose levels, and GKT13691 reduced albuminuria and oxidative stress in diabetic Lepr db/db mice. 80, 81 In other studies, another dual inhibitor of NOX-1 and NOX-4, GKT137831, protected against experimentally induced liver fibrosis, 73 and also Reduction in albuminuria and renal hypertrophy along with decreased NOX-4 and tumour-suppressor p53 expression at the protein level *Dual NOX-1 and NOX-4 inhibitor. Abbreviations: AICAR, AMP analogue; ApoE, apolipoprotein E; CKD, chronic kidney disease; CTGF, connective tissue growth factor; NF, nuclear factor; NOX, NADPH oxidase; NRf2, nuclear factor erythroid 2-related factor 2; PDTC, pyrrolidine dithiocarbamate; ROS, reactive oxygen species; STZ, streptozotocin; TGF-β, transforming growth factor β; UUO, unilateral ureteral obstruction.
reduced oxidative stress in human aortic endothelial cells. 82, 83 The role of NOX-1 in diabetes-associated vascular complications has also been evaluated in mice. 83 Deletion of Nox1 in atherosclerosis-prone, apolipoprotein E-deficient (Apoe -/-) mice with streptozotocininduced diabetes prevented the development of atherosclerotic plaques in the aorta, and similar results were reported for treatment with GKT137831 in diabetic Apoe -/-mice. By contrast, knockout of Nox4 in diabetic Apoe -/-mice did not prevent plaque formation in the aorta, suggesting that NOX-1 has a crucial role in diabetes-induced vascular complications. In addition, administration of GKT137831 to diabetic Apoe -/-mice reduced ROS production, inflammation, and expression of vascular adhesion molecules and profibrotic markers. 83 A phase I clinical trial using a single dose of GKT137831 demonstrated that it was safe and well tolerated. 84 A double-blind, randomized, placebo-controlled phase II study is underway to evaluate the effect of GKT137831 on albuminuria in patients with type 2 diabetes mellitus.
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Many studies support the concept that overproduction of NADPH oxidase isoforms is implicated in several pathological processes relevant to CKD; however, some NADPH oxidase isoforms might also elicit protective functions. In particular, the protective role of NOX-4 has been investigated. The pathogenic role of NOX-4 was questioned based on a study that used three different models of CKD (streptozotocin-induced diabetes, UUO, and 5/6 nephrectomized mice) to define the role of NOX-4 in renal fibrosis. 76 NOX-4 knockout did not reduce progression of the disease in these three models. In the streptozotocin-induced diabetes model, NOX-4 deficiency led to increased albuminuria but to a similar degree of matrix deposition in wild-type and knockout mice. In the UUO mice, renal expression of ICAM-1, CTGF, and fibronectin were higher in knockout than wild-type mice, and in the 5/6 nephrectomy model, the development of hypertension was not prevented in the knockout mice. In addition, a separate study revealed a protective role of NOX-4 in the UUO model of CKD.
85 Nox4-deficient mice exhibited extensive tubulo interstitial fibrosis, tubular apoptosis, and oxidative stress and reduced expression of anti oxidant markers, such as hypoxia-inducible factor 1α and nuclear factor erythroid 2-related factor 2; renal expression of the other NADPH oxidase isoforms remained unchanged. 85 The function of NOX-4 might, therefore, differ across the whole body, individual organs, or types of cells. Moreover, its effect might also be time-dependent, changing over the course of the disease. Although complete deletion of Nox4 might be detrimental, the body of evidence collected to date suggests that reducing NOX-4 overactivity is a worthwhile strategy in treating renal disease progression in diabetic nephropathy.
Inflammation and NF-κB signalling
As nuclear factor κB (NF-κB) activates a large number of proinflammatory genes, it is an attractive therapeutic target for the regulation of the inflammatory processes involved in CKD. New insights into NF-κB signalling and its crucial role in renal inflammation have been gained with the use of pyrrolidine dithio carbamate (PDTC), which inhibits the NF-κB pathway to block to chronic inflammation in gentamicin-treated rats and in the 5/6 nephrectomy rat model. 86, 87 In both models, PDTC treatment attenuated renal injury and renal inflammation. 86, 87 In a rat model of renal disease induced by aldosterone and salt administration, 88 PDTC treatment reduced renal injury by inhibiting the expression of genes encoding TGF-β, intercellular adhesion molecule 1 (ICAM-1), collagen IV, and CTGF, as well as expression of CTGF and ICAM-1 proteins. Although the exact mode of action of PDTC is unclear, these data reinforce the concept that NF-κB has a pivotal role in the progression of chronic renal inflammation. However, these studies only showed a partial renoprotective effect of PDTC.
The effect of celastrol, another inhibitor of NF-κB, on insulin resistance and renal function has been tested in Lepr db/db diabetic mice. 89 Celastrol is derived from a plant (Tripterygium wilfordi) used in traditional Chinese medicine that has anti-inflammatory, antioxidant, and anticancer activities. Celastrol treatment improved insulin resistance, reduced albuminuria, glomerular matrix expansion, TGF-β expression, and deposition of collagen IV in these mice. 89 Urinary levels of several pro inflammatory cytokines were also significantly decreased, as was the accumulation of renal lipids. 89 Celastrol prevents acute kidney injury (caused by ischaemia-reperfusion injury) in rats by reducing renal inflammation and tubular injury. 90 In these studies, only partial inhibition of NF-κB was observed, suggesting that the protective effects of celastrol might be mediated via combined inhibition of other inflammatory proteins such as mitogen-activated protein kinases and transcription factor AP-1. 91 Currently, no clinical trials have assessed the effects of NF-κB inhibitors in patients with CKD; however, these new data might facilitate such an approach.
Energy-sensing molecules
The kidney is prone to injury associated with states of excess caloric intake, such as diabetes and obesity, with similar renal manifestations. Structural alterations include mesangial matrix expansion, glomerulomegaly, glomerulosclerosis, thickening of the glo merular basement membrane, progressive detachment of podo cytes, renal haemodynamic alterations, inflammation, and the progressive development of interstitial fibrosis. [92] [93] [94] Functional impairment is usually characterized by increased proteinuria, as well as glomerular hyperfiltration. [94] [95] [96] For a long time, adipose tissue was considered to act as a passive fat storage depot; now, it is recognized to be an active endocrine organ that produces a number of adipokines (such as leptin and adiponectin) and TNF that are involved not only in physiological functions, such as energy and cell homeostasis and metabolism, but also in pathophysiological processes, such as inflammation and insulin resistance. 97 Numerous adipocyte-derived molecules are involved in the pathological changes leading to RAAS activation, hyperinsulinaemia, inflammation, and hormonal disturbances. 90, 98, 99 Among the adipokines, adiponectin might provide renal protection via its anti-inflammatory properties. Studies of adiponectin and its downstream signalling pathway, 5'-AMP-activated protein kinase (AMPK), have established an important causal link between metabolic disease and the development of CKD. 75 The role of AMPK in the kidney has highlighted a key pathway that links energy sensing with the development of renal inflammation and fibrosis.
AMPK in CKD and inflammation AMPK is activated in response to depletion of ATP or an increased intracellular ratio of AMP to ATP, which preserves cell survival under low-caloric conditions. 100 The central role of AMPK in mediating the effects of adiponectin was established by studies in adiponectin receptor 1 (AdipoR1)-knockout mice. 101 AMPK has a role in early renal inflammation and sustained fibrosis in mice with diet-induced obesity and renal injury. 92, 102 Potent inhibition of CCL2 (also known as MCP-1) by AMPK was observed in vivo and in mesangial cells; furthermore, activation of AMPK completely blocked lipid vacuolization in proximal tubule cells. 92 Part of the basis for this latter finding might be reduced activity of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase and reduced cholesterol production, which occurs in response to AMPK activation. 102 AMPK also seems to have a prominent role in regulating macrophage infiltration and activation. Infiltrated macrophages in the kidneys of mice fed a high-fat diet were completely reduced by AMPK activation. 92 Furthermore, AMPK activation lowered the ratio of CD11c to CD11b, indicating a reduction specifically in M1 macrophages. These observations highlight a role for AMPK in the regulation of macrophage activation, 100 which will probably become an active area of future research.
AMPK also seems to have a key role in regulating NADPH oxidase isoforms. NOX-4 is prominently expressed in podocytes, and the upregulation of NOX-4 induced by exposure to high glucose levels can be blocked by treatment with adiponectin or by activation of AMPK. 75 In other studies, activation of AMPK inhibited expression of NOX-2 subunits p67 and p47, via upregulation of IκB-α, which blocks NF-κB from stimulating expression of the genes encoding these subunits in endothelial cells. 103 A role for AMPK regulation of NOX-4 was demonstrated in diabetic nephropathy by several groups, leading to a growing consensus that NOX-4 might be the most critical NAPDH oxidase isoform linked to progression of diabetic nephropathy. 80, 104 AMPK activation and fibrosis In addition to inflammation, AMPK has also been closely linked to fibrosis-promoting pathways. In mice fed a high-fat diet, chronic activation of AMPK with the AMP analogue, AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) reduced both mesangial matrix expansion and urinary levels of TGF-β1. 102 Our group reported that AMPK activation also markedly reduced glomerular accumulation of TGF-β, collagen and fibronectin in several mouse models of diabetic nephropathy. 105 Similar findings were also observed in the OVE26 mouse model of diabetic nephropathy. 104 The mechanistic basis of how AMPK activation inhibits TGF-β is unclear at present. Adiponectin and AMPK reduce TGF-β-induced secretion of the extracellular matrix proteins collagen types I and IV and fibronectin, and also inhibits myofibroblast trans differentiation; 106 however, phosphorylation of Smad2 and Smad3 was unaffected. 106 The key transcription factor, upstream stimulatory factor 1 (USF1), is translocated to the nucleus in response to high glucose levels, and this effect is completely blocked by AMPK activation. 107 As USF1 mediates glucose-induced stimulation of TGF-β1 gene transcription, AMPK might have an important role in regulating USF1-induced TGF-β1 synthesis. 108 AMPK activation, sirtuins, and mTOR A key downstream event in AMPK activation involves stimulation of members of the sirtuin family of class III protein deacetylases, of which seven different forms have been identified (Sirt1-7). Sirt1 and Sirt3 are induced by calorie restriction, and the catalytic α-subunit of AMPK regulates sirtuin synthesis in macrophages. 109 Interestingly, Sirt3 is regulated by angiotensin receptors and might have a role in cell senescence. 110 The serine-threonine protein kinase mammalian target of rapamycin (mTOR) is activated in patients with diabetic nephropathy, 111 and inhibition of mTOR signalling prevented glomerulosclerosis and ameliorated the progression of glomerular disease in mice. 111 However, mTOR knockout in podocytes also contributes to renal disease, 111, 112 and treatment with rapamycin worsens proteinuria in some patients, 113 limiting its potential as a therapeutic agent for diabetic nephropathy. In another study, mTOR inhibition also led to reduced levels of NOX-4 in podocytes, suggesting that mTOR might directly regulate NOX-4 independently of AMPK. 114 Mitochondrial biogenesis and kidney disease A key pathway by which AMPK activation protects cells in a calorie-deprived state involves stimulating the master regulator of mitochondrial biogenesis, peroxisome proliferator-activated receptor γ co-activator 1α (PGC-1α, encoded by PPARGC1A). This transcriptional co-activator is a potent stimulator of many mitochondrial proteins, and its activation increases the mitochondrial content of the cell. 115 In states of reduced AMPK activation, PGC-1α activity would also be expected to be reduced. Indeed, PGC-1α levels are markedly reduced in muscle tissue of patients with diabetes, 116 which might result in part from epi genetic modification of the PPARGC1A promoter. PGC-1α levels are reduced in diabetic kidneys, in association with reduced AMPK, reduced mitochondrial content, and reduced mitochondrial complex activity. 105 This observation has led researchers to question whether mitochondrial complex activity in the electron transport chain is also reduced, and whether a concomitant change might occur in mitochondrial superoxide production. Indeed, when our group conducted real-time imaging of diabetic kidneys, we showed that superoxide production was reduced; this finding was further verified in ex vivo studies using electron paramagnetic resonance measurements. 105 These observations indicate that the diabetic kidney is actually in a state of reduced mitochondrial activity with reduced mitochondrial superoxide production, in direct contrast to the prevailing notion that diabetic complications result from an excess of mitochondrial superoxide. Clearly, the question of mitochondrial superoxide production will need to be further addressed in CKD using tools that can accurately measure superoxide production in vivo and in specific subcellular compartments.
In other work, our research group obtained an index of mitochondrial activity in patients with established diabetic nephropathy by quantitative measurements of a variety of metabolites linked to various relevant biochemical pathways. 117 The predominant signature identified was a reduction in metabolites produced by mitochondrial enzymes. Semiquantitative analysis revealed a reduction in mitochondrial complex IV in kidney biopsy samples from patients with diabetic nephropathy. Furthermore, PPARGC1A expression was shown to be reduced in kidney tissues from patients with diabetic nephropathy, but not in those from patients with minimal change disease. 117 These studies have established a new paradigm for understanding diabetic nephropathy. An early and progressive reduction in mitochondrial content, potentially driven by reduced activity of AMPK and PGC-1α, seems to be linked to early renal inflammation and profibrotic pathways. Results from animal studies suggest that reversal of these features is beneficial, and similar approaches might be useful in treating patients with diabetes as well. Of note, nonpharmacological means of increasing AMPK activity (such as exercise and caloric restriction) reduce diabetic nephropathy independent of weight loss and glucose lowering. 118 Novel activators of AMPK are under investigation. For example, ZNL024 (a small-molecule allosteric activator of AMPK) has beneficial effects in mice. 119 In this study, Lepr db/db diabetic mice treated with ZNL024 demonstrated improved glucose tolerance, reduced liver weight, and decreased liver content of total cholesterol and triacyl glycerol. 119 Valproic acid, a potent anti epileptic agent, is effective in activating AMPK in vitro and in vivo. 120 Treatment of Lep ob/ob hyperphagic obese mice with valproic acid significantly reduced plasma glucose levels and decreased both liver mass and fat content, owing to AMPK activation. 120 Further studies will need to be conducted to define the role of these agents in activating AMPK in different stages of CKD.
Conclusions
The exciting new research linking energy-sensing pathways, kidney inflammation, and fibrosis suggest novel paradigms in the approach to treating CKD. Activation of the AMPK-sirtuin-PGC-1α pathways and inhibition of mTOR will probably find a place in the treatment of metabolic disorders as well as various types of progressive kidney disease. Anti-inflammatory approaches to mitigate NF-κB activation and NOX activity using oral inhibitors are promising. Oral agents that inhibit fibrosis and vascular calcification via multiple mechanisms of action might prove valuable adjuncts to currently available therapies in patients with moderate to advanced stages of CKD. In addition, molecules identified by microRNA and metabolomic analysis might serve as useful targets for new therapies, as well as markers for monitoring disease progression. Coupled with the advances in biomarker research and the close collaboration of academia, industry, and government agencies, the coming years could herald a new era of drug discovery in the treatment of CKD.
Review criteria
PubMed and MEDLINE databases were searched for papers in the English language published from 1985 to 2014, using the following keywords: "diabetic nephropathy", "chronic kidney disease", "end-stage renal disease", "renin-angiotensin system", "NADPH oxidase", "pirfenidone", "tranilast", "cell division autoantigen", "fibrosis", "transforming-growth factor-β", "connective tissue growth factor", "BMP-7", "HGF", "vascular calcification", "Klotho", "AMPK", "mitochondrial biogenesis", "therapy" and "drug". Some references were identified from relevant articles. The references included in this Review were selected on the basis of clinical interest and importance, accuracy of the data, and the methodological quality of the study.
